Kura Oncology Inc (KURA) Noticias

Form 8-K - Current report

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kura Oncology Reports Third Quarter 2024 Financial Results

– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025;...

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation...

Kura Oncology to Report Third Quarter 2024 Financial Results

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L...

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

Form 3 - Initial statement of beneficial ownership of securities